Last reviewed · How we verify
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Details
| Lead sponsor | Bayer |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 262 |
| Start date | Mon Feb 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jun 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pulmonary Hypertension
Interventions
- Riociguat (Adempas, BAY63-2521)
- Placebo
Countries
Italy, Japan, Taiwan, Poland, South Korea, Denmark, Netherlands, Russia, Belgium, Mexico, Portugal, United States, France, Slovakia, Austria, Argentina, Canada, Brazil, Spain, United Kingdom, Germany, Switzerland, Australia, China, Turkey (Türkiye), Czechia